Santen Pharmaceutical Co., Ltd. Q2 FY2021 Financial Results

Shigeo Taniuchi, President & Chief Executive Officer
Kazuo Koshiji, Senior Corporate Officer, Corporate Administration, Chief Financial Officer, Head of Finance and Administration Division
Satoshi Suzuki, Senior Corporate Officer, Head of Corporate Development Division
Kenji Morishima, Corporate Officer, Head of China Product Development Department

PLAY LIST

from the beginning

Q2 FY2021 Financial Results

CORE PRINCIPLE and WORLD VISION

Santen 2030 Toward 2030 and beyond

Evolution from Vision 2020 to Santen 2030

1. Steady Progress Toward MTP2025

Financial Summary

Agenda

(1) Profit Ratio Improvement in Core Businesses: Japan Business-1

(1) Profit Ratio Improvement in Core Businesses: Japan Business-2

(1) Profit Ratio Improvement in Core Businesses: Japan Business-3

(1) Profit Ratio Improvement in Core Businesses: Japan Business-4

(1) Profit Ratio Improvement in Core Businesses: China Business-1

(1) Profit Ratio Improvement in Core Businesses: China Business-2

(1) Profit Ratio Improvement in Core Businesses: Asia and EMEA Business

(2) Expansion of New Areas: Americas-1

(2) Expansion of New Areas: Americas-2

(3) Strengthening of Foundation as a Global Company-1

(3) Strengthening of Foundation as a Global Company-2

Financial Results

Financial Results-1

Financial Results-2

FY2021 Forecasts

Shareholder Return

Back
Next

Download

Presentation File(PDF 1.6 MB)